AstraZeneca Pharma India gets DCGI nod to market cancer drug in India

New Delhi: Drug firm AstraZeneca Pharma India today said it has received permission from the Drug Controller General of India (DCGI) to import and market olaparib tablets used for the treatment of ovarian and breast cancer. The permission from the DCGI is for olaparib (Lynparza) tablets in the strengths of 100 mg and 150 mg, AstraZeneca Pharma India said in a BSE filing.

The tablets are a patented product of the AstraZeneca group, it added.

“The import and market permission for olaparib is a significant milestone for women in India living with platinum-sensitive relapsed ovarian cancer and BRCA-mutated HER-2 negative metastatic breast cancer, which has historically been difficulty-to-treat diseases,” AstraZeneca Pharma India MD Gagan Singh said.

Shares of AstraZeneca Pharma India today closed at Rs 1,710.30 per scrip on BSE, up 1.59 per cent from their previous close.

  • Related Posts

    Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test

    Basel- Roche announced today that the cobas® MPX-E assay, a qualitative in-vitro test for the detection and discrimination of Human Immunodeficiency Virus (HIV 1 and 2) and Hepatitis C, B,…

    Haryana Mandates Real-Time Medicine Tracking In Govt Hospitals

    Chandigarh: In a major push to strengthen public healthcare, the Haryana Government has directed all government hospitals to maintain medicine stock records on a real-time centralised portal, ensuring transparency and…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test

    Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test

    Haryana Mandates Real-Time Medicine Tracking In Govt Hospitals

    Haryana Mandates Real-Time Medicine Tracking In Govt Hospitals

    Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

    Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

    Diabetic drug metformin found to act on brain

    Diabetic drug metformin found to act on brain

    Hetero debuts semaglutide generic in emerging markets

    Hetero debuts semaglutide generic in emerging markets

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial